(UPDATED) Ischemia with no obstructive coronary arteries (INOCA) produces symptoms that affect physical functioning, mental health, and quality of life, a new survey of patients diagnosed with the ...
Empagliflozin reduced proinflammatory cytokines and oxidative stress markers in INOCA patients with CMD, improving vascular health. Treatment led to favorable shifts in endothelial extracellular ...
The October 25, 2022, Yale Cardiovascular Medicine Grand Rounds, “Seeing the Invisible: Ischemia and No Obstructive Coronary Artery Disease,” was presented by Samit Shah, MD, PhD, assistant professor ...
BETHESDA, Md., March 30, 2026--(BUSINESS WIRE)--CorVista Health, a leader in noninvasive cardiovascular diagnostics, today announced new data evaluating a physiologic signal–based machine-learning ...
NEW ORLEANS — Coronary function testing performed in patients with symptomatic ischemia but nonobstructive arteries has a high diagnostic yield, is safe, and often leads to treatment that improves ...
Please provide your email address to receive an email when new articles are posted on . Learning from women’s experiences may be key to improving INOCA diagnosis and care. Four themes that may improve ...
Please provide your email address to receive an email when new articles are posted on . RANCHO PALOS VERDES, Calif. — Observational studies show ischemia with no obstructive CAD is “common” among ...
CHICAGO, November 05, 2025--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be ...
For patients with moderate-to-severe ischemia but without obstructive coronary disease, the so-called INOCA patient, there is no correlation between the severity of ischemia on stress echocardiography ...
A new study led by investigators at the Smidt Heart Institute at Cedars-Sinai found symptoms of the increasingly common cardiovascular condition known as ischemia with no obstructive coronary arteries ...
CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring new frontiers for GLP-1 drugs in cardiovascular medicine, and foundational ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results